MASP-2 is under clinical development by Omeros and currently in Phase I for Age Related Macular Degeneration. According to GlobalData, Phase I drugs for Age Related Macular Degeneration have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MASP-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small molecules are under development for the treatment of atypical hemolytic uremic syndrome (aHUS), hematopoietic stem-cell transplant-associated thrombotic microangiopathy, Immunoglobulin A (IgA) nephropathy (IgAN) and age related macular degenetation. The drug candidate is administered by both oral and intravenous routes. It acts by targeting mannan binding lectin serine protease 2 (MASP-2).
Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.
For a complete picture of MASP-2’s drug-specific PTSR and LoA scores, buy the report here.